Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease with increasing
incidence; the median survival is only 35 months and as yet no therapy has been proven to …

Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic disease, with no effective
treatment and a median survival time of 2–5 yrs. The search for effective treatment has …

Idiopathic pulmonary fibrosis (IPF) is the most prevalent of the idiopathic interstitial
pneumonias and its incidence seems to be increasing [1–4]. IPF is generally considered to …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease, characterised by progressive scarring of the lung and associated with a high …

Idiopathic pulmonary fibrosis (IPF) is a devastating condition with a 5‐year survival of
approximately 20%. The disease primarily occurs in elderly patients. IPF is a highly …

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease. A major
breakthrough in treatment came when, after decades of clinical trials which failed to identify …

In 2014, two landmark clinical trials (ASCEND and INPULSIS) were published
demonstrating, for the first time, a treatment benefit for patients with idiopathic pulmonary …

ABSTRACT Introduction Idiopathic Pulmonary Fibrosis (IPF) is a progressive and
devastating lung disease, characterized by progressive lung scarring. Areas covered Prior to …

Over the past two and a half decades, many clinical trials have been designed to determine
the safety and efficacy of pharmacotherapy for patients with idiopathic pulmonary fibrosis …

Over the past decade, there has been a cohesive effort from patients, physicians, clinical
and basic scientists, and the pharmaceutical industry to find definitive treatments for …